Want to see ORMP full AI Analyst Report?

Oramed Pharm (ORMP) Price & Analysis

Q: What was Oramed Pharmaceuticals’s price range in the past 12 months?

Oramed Pharmaceuticals lowest stock price was $1.98 and its highest was $5.19 in the past 12 months.

Q: What is Oramed Pharmaceuticals’s market cap?

Oramed Pharmaceuticals’s market cap is $186.36M.

Q: When is Oramed Pharmaceuticals’s upcoming earnings report date?

Oramed Pharmaceuticals’s upcoming earnings report date is Jul 14, 2027 which is in 331 days.

Q: How were Oramed Pharmaceuticals’s earnings last quarter?

Oramed Pharmaceuticals released its earnings results on Jul 15, 2026. The company reported $1.839 earnings per share for the quarter, beating the consensus estimate of $0.43 by $1.409.

Q: Is Oramed Pharmaceuticals overvalued?

According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Oramed Pharmaceuticals pay dividends?

Oramed Pharmaceuticals pays a Notavailable dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Oramed Pharmaceuticals dividends here

Q: What is Oramed Pharmaceuticals’s EPS estimate?

Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Oramed Pharmaceuticals have?

Oramed Pharmaceuticals has 41,597,355 shares outstanding.

Q: What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?

Oramed Pharmaceuticals reported an EPS of $1.839 in its last earnings report, beating expectations of $0.43. Following the earnings report the stock price went up 1.5%.

Q: Which hedge fund is a major shareholder of Oramed Pharmaceuticals?

Currently, no hedge funds are holding shares in ORMP

534 Followers

ORMP Stock Chart & Stats

$4.03

-$0.13(-3.12%)

At close: Jul 24 4:00 PM EDT

$4.03

-$0.13(-3.12%)

Day’s Range― - ―

52-Week Range$1.98 - $5.19

Previous Close$4.03

Volume134.46K

Average Volume (3M)210.74K

Market Cap

$186.36M

Enterprise Value$154.55

Total Cash (Recent Filing)$16.09M

Total Debt (Recent Filing)$733.00K

Price to Earnings (P/E)1.1

Beta0.44

Next Earnings

Jul 14, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.23

Shares Outstanding41,597,355

10 Day Avg. Volume339,860

30 Day Avg. Volume210,739

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.59

Price to Sales (P/S)59.00

P/FCF Ratio-10.65

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda<0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.71

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

InvestmentThe joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.

Joint VentureOramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.

Bears Say

Clinical EfficacyThe candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.

Oramed Pharm News

Oramed Pharm Updates Bylaws, Streamlining Shareholder Actions

Oramed Pharm ( ($ORMP) ) has shared an announcement. On June 28, 2026, Oramed Pharmaceuticals’ board approved Fifth...

2M ago

ORMP

Oramed to join Russell 2000 and 3000 indexes

Oramed (ORMP) Pharmaceuticals announced that it is set to join the U.S. small cap Russell 2000 and broad-market...

2M ago

ORMP

Oramed Pharmaceuticals Delays Quarterly SEC Filing

Oramed Pharm ( ($ORMP) ) has released a notification of late filing. Oramed Pharmaceuticals Inc. has filed a...

3M ago

ORMP

Oramed Completes Oratech Sale and Strategic Lifeward Financing

Oramed Pharm ( ($ORMP) ) just unveiled an update. On March 25, 2026, Lifeward Ltd. completed its previously...

5M ago

ORMP

Lifeward closes strategic partnership agreement with Oramed

Lifeward (LFWD) announced that it has closed on the company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals...

5M ago

LFWD

ORMP

Lifeward receives shareholder approval to close on partnership with Oramed

Lifeward (LFWD) announced that its shareholders approved the issuances of ordinary shares of the Company in connection with...

5M ago

LFWD

ORMP

Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal

The latest announcement is out from Oramed Pharm ( ($ORMP) ). On February 19, 2026, Oramed Pharmaceuticals entered...

6M ago

ORMP

Oramed Pharm pivots with Lifeward strategic platform deal

The latest update is out from Oramed Pharm ( ($ORMP) ). On January 12, 2026, Oramed Pharmaceuticals entered...

7M ago

ORMP

Oramed and Lifeward sign strategic transaction

Oramed (ORMP) and Lifeward (LFWD) signed binding agreements for a strategic transaction between Oramed, Lifeward and a certain...

7M ago

LFWD

ORMP

Oramed Pharm Announces Dividend After Scilex Payment Gain

Oramed Pharm ( ($ORMP) ) has provided an update. On January 7, 2026, Oramed Pharmaceuticals reported receiving an...

7M ago

ORMP

Oramed receives $18M payment from Scilex Holdings

Oramed (ORMP) Pharmaceuticals announced it has received an $18M payment from Scilex Holdings, representing full satisfaction of obligations...

7M ago

ORMP

Oramed declares cash dividend payment of 25c per share

Oramed’s (ORMP) Board of Directors has approved a cash dividend payment of 25c per share to reward shareholders....

7M ago

ORMP

Oramed Pharm Announces Long-Tenured Director’s Upcoming Resignation

Oramed Pharm ( ($ORMP) ) just unveiled an update. On December 31, 2025, Oramed Pharmaceuticals Inc. announced that...

8M ago

ORMP

Oramed Pharm Completes Warrant Sale, Boosting Liquidity

An announcement from Oramed Pharm ( ($ORMP) ) is now available. On July 22, 2025, Oramed Pharmaceuticals Inc....

8M ago

ORMP

ORMP FAQ

What was Oramed Pharmaceuticals’s price range in the past 12 months?

Oramed Pharmaceuticals lowest stock price was $1.98 and its highest was $5.19 in the past 12 months.

What is Oramed Pharmaceuticals’s market cap?

Oramed Pharmaceuticals’s market cap is $186.36M.

When is Oramed Pharmaceuticals’s upcoming earnings report date?

Oramed Pharmaceuticals’s upcoming earnings report date is Jul 14, 2027 which is in 331 days.

How were Oramed Pharmaceuticals’s earnings last quarter?

Oramed Pharmaceuticals released its earnings results on Jul 15, 2026. The company reported $1.839 earnings per share for the quarter, beating the consensus estimate of $0.43 by $1.409.

Is Oramed Pharmaceuticals overvalued?

According to Wall Street analysts Oramed Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Oramed Pharmaceuticals pay dividends?

Oramed Pharmaceuticals pays a Notavailable dividend of $0.25 which represents an annual dividend yield of N/A. See more information on Oramed Pharmaceuticals dividends here

What is Oramed Pharmaceuticals’s EPS estimate?

Oramed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oramed Pharmaceuticals have?

Oramed Pharmaceuticals has 41,597,355 shares outstanding.

What happened to Oramed Pharmaceuticals’s price movement after its last earnings report?

Oramed Pharmaceuticals reported an EPS of $1.839 in its last earnings report, beating expectations of $0.43. Following the earnings report the stock price went up 1.5%.

Which hedge fund is a major shareholder of Oramed Pharmaceuticals?

Currently, no hedge funds are holding shares in ORMP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oramed Pharm Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

128.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (ORMP) is a clinical-stage biopharmaceutical company focused on developing oral drug delivery platforms and orally ingestible therapeutics, with a primary emphasis on oral formulations of biologic medicines such as insulin for the treatment of diabetes. The company operates in the biotechnology/pharmaceutical R&D sector and advances product candidates through clinical development while also engaging in collaborations related to its oral delivery technology.